Karyopharm Therapeutics (KPTI) Competitors $4.61 +0.25 (+5.73%) Closing price 04:00 PM EasternExtended Trading$4.62 +0.00 (+0.11%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. BIOA, IKT, BDTX, ALEC, TIL, GALT, LXEO, KYTX, RAPT, and LYELShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioAge Labs (BIOA), Inhibikase Therapeutics (IKT), Black Diamond Therapeutics (BDTX), Alector (ALEC), Instil Bio (TIL), Galectin Therapeutics (GALT), Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors BioAge Labs Inhibikase Therapeutics Black Diamond Therapeutics Alector Instil Bio Galectin Therapeutics Lexeo Therapeutics Kyverna Therapeutics Rapt Therapeutics Lyell Immunopharma Karyopharm Therapeutics (NASDAQ:KPTI) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Does the media refer more to KPTI or BIOA? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for BioAge Labs. Karyopharm Therapeutics' average media sentiment score of 0.47 beat BioAge Labs' score of -0.35 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, KPTI or BIOA? BioAge Labs has lower revenue, but higher earnings than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.27-$76.42M-$13.26-0.35BioAge LabsN/AN/A-$71.11MN/AN/A Is KPTI or BIOA more profitable? BioAge Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-43.99% N/A -35.95% BioAge Labs N/A N/A N/A Do insiders and institutionals have more ownership in KPTI or BIOA? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 3.0% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 20.8% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend KPTI or BIOA? Karyopharm Therapeutics currently has a consensus price target of $43.20, indicating a potential upside of 837.09%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Karyopharm Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryKaryopharm Therapeutics beats BioAge Labs on 7 of the 11 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.67M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.358.7226.1719.90Price / Sales0.27663.86414.67113.66Price / CashN/A151.5836.1356.90Price / Book-0.214.548.055.38Net Income-$76.42M$31.16M$3.15B$248.50M7 Day Performance2.67%0.15%1.85%2.97%1 Month Performance11.89%8.81%4.81%6.02%1 Year Performance-61.58%2.55%34.86%20.39% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.1668 of 5 stars$4.61+5.7%$43.20+837.1%-64.4%$37.67M$145.24M-0.35380News CoverageBIOABioAge LabsN/A$4.13-1.7%N/AN/A$148.06MN/A0.00N/ANews CoverageAnalyst DowngradeIKTInhibikase Therapeutics1.3478 of 5 stars$1.95+20.4%$6.50+233.3%+56.0%$144.97M$260K-0.736News CoverageBDTXBlack Diamond Therapeutics3.1192 of 5 stars$2.48+5.5%$14.60+488.7%-47.2%$141.01MN/A41.3390Positive NewsAnalyst UpgradeALECAlector4.1092 of 5 stars$1.40-5.4%$4.00+185.7%-67.9%$139.99M$100.56M-1.11270TILInstil Bio3.404 of 5 stars$20.83-9.3%$119.00+471.3%+112.9%$136.62MN/A-1.74410News CoverageGap UpGALTGalectin Therapeutics1.8379 of 5 stars$2.11-9.4%$6.00+184.4%-5.5%$133.54MN/A-2.939Gap UpLXEOLexeo Therapeutics2.4974 of 5 stars$4.02-2.4%$16.60+312.9%-73.0%$133.46M$650K-1.2258News CoverageKYTXKyverna Therapeutics2.0596 of 5 stars$3.07-6.4%$18.50+502.6%-64.5%$132.69M$7.03M-0.9196News CoverageRAPTRapt Therapeutics4.1756 of 5 stars$8.00-5.1%$24.00+200.0%-68.2%$132.32M$1.53M-0.4280LYELLyell Immunopharma3.3299 of 5 stars$8.84-1.1%$15.00+69.7%-70.2%$130.92M$60K-0.35270 Related Companies and Tools Related Companies BioAge Labs Competitors Inhibikase Therapeutics Competitors Black Diamond Therapeutics Competitors Alector Competitors Instil Bio Competitors Galectin Therapeutics Competitors Lexeo Therapeutics Competitors Kyverna Therapeutics Competitors Rapt Therapeutics Competitors Lyell Immunopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
